Graft rejection is due, amongst other things, to activation of T lymphocytes by Interleukin 2. IL2 interacts with the CD25 receptor of the lymphocyte membrane.
Basiliximab, like Dacluzimab, are anti CD25 monoclonal antibodies that protect this receptor against IL2
Anti CD 25 monoclonals may be effective also in immunity linked diseases such as Multiple sclerosis, asthma, ulcerative colitis, Crohn, Diabetes, Rhumatoid arthritis
